HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness	Arthritis, Gouty, Chemically-Induced Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Crystal Arthropathies, Drug Eruptions, Drug-Related Side Effects and Adverse Reactions, Erythema, Hypersensitivity, Delayed, Hyperuricemia, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Stevens-Johnson syndrome, Stomatognathic Diseases, arthritic joint disease, arthropathy, dermatitis, drug allergy, erythema multiforme, gout, hereditary disease, immune system disorder, inborn disorder of purine or pyrimidine metabolism, inborn errors of metabolism, metabolic disease, mouth disorder, musculoskeletal system disorder, rheumatic disorder, skin disorder, stomatitis, vesiculobullous skin disease	Not yet recruiting	Phase 4	2026-01-27		NCT07369622

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Haiphong University of Medicine and Pharmacy	7

0 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
No products are listed yet.